Kinematic measures provide useful information after intracranial aneurysm treatment by Raw, RK et al.
This is an author produced version of Kinematic measures provide useful information after
Intracranial Aneurysm Treatment (IAT).
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/123045/
Article:
Raw, RK, Wilkie, RM orcid.org/0000-0003-4299-7171, Mon-Williams, M 
orcid.org/0000-0001-7595-8545 et al. (4 more authors) (2017) Kinematic measures 
provide useful information after Intracranial Aneurysm Treatment (IAT). Journal of 
Rehabilitation and Assistive Technologies Engineering. ISSN 2055-6683 (In Press) 
© 2017. This is an author produced version of a paper accepted for publication in Journal 
of Rehabilitation and Assistive Technologies Engineering. Uploaded in accordance with the
publisher's self-archiving policy. 
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
                                          IAT kinematic outcome measures 
 
1 
 
Kinematic measures provide useful information after Intracranial 
Aneurysm Treatment (IAT) 
 
Rachael K. Raw1*, Richard M. Wilkie1, Mark Mon-Williams1, Stuart A. Ross2, Kenan 
Deniz2, Tony Goddard2 and Tufail Patankar2 
 
1 School of Psychology, University of Leeds, Leeds, UK. 
2
 Department of Neurosciences, Leeds General Infirmary, Leeds, UK.  
* Corresponding author:  Telephone: (+44) 7780652723   Email: pscrkr@leeds.ac.uk 
 
Abstract  
Current methods of assessing the outcomes of Intracranial Aneurysm Treatment (IAT) for 
Aneurysmal Subarachnoid Haemorrhage (aSAH) are relatively insensitive, and thus unlikely 
to detect subtle deficits. Failures to identify cognitive and motor outcomes of IAT might prevent 
delivery of optimal post-operative care. There are also concerns over risks associated with 
using IAT as a preventative measure.  We explored whether our kinematic tool would yield 
useful information regarding motor/cognitive function in patients who underwent IAT for aSAH 
or Unruptured Aneurysm (UA). Computerised kinematic motor and learning tasks were 
administered alongside standardised clinical outcome measures of cognition and functional 
ability, in ten patients, as a pilot trial. Tests at post-IAT discharge and six-week follow-up were 
compared to see which measures detected changes. Kinematic tests captured significant 
improvements from discharge to six-week follow-up, indexed by reduced motor errors and 
improved learning. Increased $GGHQEURRNH¶V&RJQLWLYH([DPLQDWLRQ-Revised scores reflected 
some recovery of memory function for most individuals, but other standardised cognitive 
measures, functional outcome scores and a psychological questionnaire showed no changes. 
Kinematic measures can identify variation in performance in individuals with only slightly 
improved abilities post-IAT. These measures may provide a sensitive way to explore post-
operative outcomes following IAT, or other similar surgical procedures.  
 
Key Words: Stroke, Intracranial Aneurysm, Subarachnoid Haemorrhage, Kinematic Analysis, 
Stroke Rehabilitation. 
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Introduction  
Previously we have shown that our Kinematic Assessment Tool (KAT) can reliably distinguish 
between poor and proficient performance in adults and children, with and without neurological 
impairment. 1-7 Utilising kinematic analysis technology, KAT allows many of the properties of 
a given movement to be independently and objectively assessed. This way, we can empirically 
describe the qualities of a movement beyond making a judgement at a functional level, on 
whether it has been successful or unsuccessful. Specifically, KAT captures the horizontal and 
vertical movements of the hand (X and Y coordinates) as participants carry out visual-spatial 
tasks, and independently records various kinematic outcomes (e.g. reaction time, movement 
speed, accuracy, pressure etc) through its integration with any commercially available tablet 
PC. 1 When installed on a tablet laptop, the screen can be rotated and folded backwards to 
allow participants to interact in a manner reminiscent of using a pen and paper, which is 
practical for use with a diverse range of populations. The portability of the system makes it 
particularly suitable for working in clinical settings, where assessment often takes place at 
bedside and/or in outpatient clinics. Most importantly, analysing motor control (and indeed 
cognitive performance) at this level of detail provides a basis for developing specific 
hypotheses about the characteristics that determine functional success versus failure with a 
given task, and in turn, provides information about the parameters that must be targeted by 
rehabilitative interventions. 
In school settings, KAT has proven particularly successful,5 and is demonstrably far superior 
to non-computerised (e.g. pen-and-paper) tests. Furthermore, in healthy older adult groups, 
KAT can identify age-related decline in motor ability, 3,4,6 as well as changes in cognitive 
function. 7 What is uncertain, however, is the extent to which this method can be used in clinical 
populations. It has been established that KAT is useful in establishing the motor ability of 
\RXQJFKLOGUHQDQGHYHQSUHGLFWLQJ WKH UHODWLRQVKLSEHWZHHQDFKLOG¶VPRWRUVNLOODQGZHOO-
being, 8 but few studies have examined the efficacy of this form of kinematic analysis in the 
context of stroke, and we are unsure of whether kinematics measures can be used to inform 
rehabilitation. In the present small-scale pilot study, we therefore aimed to test the value of 
KAT in a group of patients that underwent Intracranial Aneurysm Treatment (IAT) ± the 
outcomes of which are relatively uncertain. 9 
Aneurysmal Subarachnoid Hemorrhage (aSAH) is a type of stroke that occurs when an 
Intracranial Aneurysm (IA) bursts, causing blood to leak into the subarachnoid space (i.e. the 
area between the Arachnoid membrane and Pia layers of the protective meninges). The 
overall incidence of aSAH in the western world is 6-8 per 100,000 per year 10, with 
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approximately 50% overall mortality. 9 Survival is associated with long-term deficits in cognitive 
function (particularly language and memory.) 9,11 Treatment options include endovascular 
techniques, where aneurysms are filled with coils under X-ray control; and neurosurgical 
clipping, which involves opening the skull, dissecting through the brain spaces and placing a 
clip across the aneurysm neck. 12 Both options aim to prevent re-bleeding and are used to 
treat aSAH. These techniques are also used to treat µasymptomatic¶ patients who electively 
undergo IAT as a preventative measure.  
While IAT for aSAH is associated with improved survival, especially when applied one-to-three 
days after a haemorrhage, 13,14 the long-term outcomes (and their neurological correlates) 
associated with IAT are poorly understood. 1 Patients with aSAH rarely resume their previous 
lifestyle due to residual functional problems, 15 ± with 50% of survivors failing to return to the 
same level of employment. 16,17 Crucially, current methods of assessing the outcomes of aSAH 
are crude, meaning patients can slip µunder the radar¶ because the long-term difficulties they 
face are not detected in the short post-operative period. For example, patients may be 
classified as having 'zero disability' by immediate post-treatment tests, whilst still experiencing 
deficits in cognition, language and memory, the extent of which can predict Quality of Life 
(QoL) and functional ability. 17,18 
The Glasgow Outcome Scale (GOS),19 which scores patients 1-5 (1 = Dead, 5 = Good 
Recovery) for µOHYHORIGLVDELOLW\¶ is often used as a global marker of recovery, where a patient 
VFRULQJ µ¶ VKRXOG EH DEOH WR UHVXPH µnormal¶ daily life, albeit with the possibility of minor 
neurological deficits. Though this provides an overall prediction of recovery, subjective scales 
like GOS are not sensitive enough to capture any subtle motor or cognitive changes, nor are 
they able to detect and/or describe psychological symptoms.20,21 Patients who have 
µUHFRYHUHG¶(based on GOS scores) may therefore have problems that emerge years after IAT 
when the patient is outside specialist services, making treatment more difficult. This is 
concerning given that a delay in treatment can cause a deterioration in physical and mental 
health,18 and greater recovery is usually achieved when rehabilitation programmes start 
early.22 
The patient group most vulnerable to the insensitivities of current post-treatment tests is likely 
to be comprised of individuals with Unruptured Intracranial Aneurysms (UA). These 
aneurysms can lie dormant for many years, and typically go un-detected until a patient has a 
brain scan, usually for an un-related diagnostic reason. Patients are then faced with the 
decision to have their aneurysm treated to avoid rupture, or they can µwatch and wait¶. The 
likelihood of a UA bursting is predominantly related to aneurysm-specific characteristics 
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(namely size and location) and to WKHSDWLHQWV¶SULRUKLVWRU\RID6$+LHwhether a different 
UA has ruptured previously 23). The risk of aSAH in untreated UA also increases with each 
year of life. 24 These points must be carefully considered when making a choice about 
treatment, especially considering WKHUHFHQWµ$58%$¶WULDO (µA Randomized trial of Unruptured 
Brain Arteriovenous malformations¶), which suggests that medical management of UA (as 
opposed to interventional methods) might be less likely to cause critical side effects, such as 
neurological deficits and post-operative stroke. 25 
 
Unsurprisingly, one of the most common questions that patients ask when diagnosed with UA 
regards the extent to which IAT might affect their QoL. Some research implies IAT for UA is 
safe (e.g. an observational study reported low mortality, no risk of neurological deficit and 
successful obliteration of the UA in just under 90% of cases 26); though to the authors¶ 
knowledge, no trial has yet included a set of neuropsychological tests to examine subtle 
outcomes of IAT in an UA group. Furthermore, anecdotal reports from the clinic suggest that 
IAT for UAs can yield post-operative side effects, with patients citing changes of a mild 
psychological and cognitive nature (e.g. forgetfulness, anxiety and µnot feeling quite the 
same¶). Indeed, the importance of developing sensitive post-treatment measures is particularly 
pertinent in this elective UA group because (i) DSDWLHQWV¶GHFLVLRQWRJRDKHDG with IAT must 
be based on the correct information about recovery; and (ii) clinicians need to be informed 
about the nature of changes induced by IAT for UA if effective rehabilitation of patients is to 
be undertaken.  
 
It is clearly essential that sensitive outcome measures are developed for use in aSAH and UA 
populations alike; which is why we selected this group to examine the efficacy of KAT for 
assessing post-operative outcomes. The present study involved two types of kinematic task ± 
firstly a collection of Motor Tests that can identify poor and proficient motor performance in 
older and younger adults, 5 and secondly a Sequence Learning Task designed to measure 
complex sequence learning as a marker of cognitive ability. 7 The tests were administered to 
UA and aSAH patients on the day of discharge from hospital µDLVFKDUJH¶ and again at six 
weeks post-IAT µ¶). A sensitive measure should be able to detect changes in 
performance, as well as identify individuals that fail to improve. We predicted that most 
patients would initially experience impaired motor and cognitive performance (caused by 
factors associated with IAT) but then show improvements after a period of recuperation. 
Standardised clinical measures of cognition, functional ability and psychological symptoms 
were administered alongside the kinematic measures of motor performance and learning.   A 
standardised self-report questionnaire on psychological symptoms was also completed by 
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participants, to measure the anxiety and depression symptoms that aSAH and UA patients 
often mention.  
 
Methods  
The study was approved in the UK by The Leeds Teaching Hospitals NHS Trust Research 
and Development Ethics Committee (LTHT R&D Number: PY13/11002; REC reference: 
14/YH/0009) confirmed on 12/03/2014. Participants (including patients and healthy controls) 
provided written informed consent in accordance with the Declaration of Helsinki. 
Participants 
Ten patients (7 females; 3 males) aged 24-72yrs (mean = 52.80, SD = 16.29) formed an 
opportunistic sample. The sample size (N=10) was based on our previous work using 
kinematic measures of motor ability in older and younger healthy adults that has demonstrated 
reliable group differences. 3 Nine patients were right-handed, indicated by the Edinburgh 
Handedness Inventory (EHI; mean score excluding left-handed patient = 89.9 of 100, SD = 
VFRUHVLQGLFDWHULJKW-handedness 27). Six patients underwent IAT for aSAH (one 
neurosurgical; five endovascular) and four underwent IAT for UA (one neurosurgical; three 
endovascular). Patients were recruited prior to IAT, or when recovering on the ward, and met 
the IROORZLQJLQFOXVLRQFULWHULDL\HDUVROGLL'LDJQRVHGZLWK8$RUD6$+LGHQWLILHGE\
Computerized Tomographic Angiography; (iii) Underwent IAT with standardised method under 
general anaesthesia; (iv) No neurological disability from previous strokes/haemorrhage; (v) 
No intracranial tumour; (vi) No previous craniotomy; (vii) No cognitive deficit (indicated by 
VFRUHVRQ0LQL0HQWDO6WDWH(YDOXDWLRn 28 (viii) No ophthalmological problems; (ix) 
Capable of personally consenting; (x) Able to work unsupported with a stylus/mouse for 20min. 
Further to the inclusion criteria, a Clinical Recovery Score (CRS 29,30) was administered to 
GHWHUPLQHSDWLHQWV¶ µUHDGLness for discharge', and recovery from general anaesthesia ± all 
patients included in the study had to meet the CRS cut-off score of 11/12 to ensure equal 
suitability for participation across individuals. One patient asked to withdraw from the study, 
as when it was time for their procedure, they did not feel well enough physically or emotionally 
to be involved. The ACE-R, SRBI and HADs (see Standardised Clinical Outcome Measures 
section) were not administered to two patients because of logistical issues. To identify whether 
patients were capable of responding with µnormal¶ levels of cognitive and motor performance 
on the kinematic tests, a second opportunistic sample formed a µcontrol group¶, consisting of 
healthy people recruited from the local community in Leeds (N = 35, with the same average 
age as the patients (mean = 53.48yrs, SD = 21.6).  
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Measures and Data Collection 
Consent was obtained from everyone at the point of testing. Healthy controls were tested in 
an office environment, seated at a table and chair. For patients, tests were administered for 
WKHILUVWWLPHLHµ'LVFKDUJH¶DWEHGVLGHRULQEHGZLWKthe computerised tasks appearing on 
a laptop, and pen-and-paper questionnaires placed on the pull-across table (standardised 
Clinical Outcome Measures were delivered first, immediately followed by the Kinematic Motor 
Tests). 7DVNVZHUH WKHQDGPLQLVWHUHGDJDLQVL[ZHHNV ODWHU µ¶with patients this time 
seated at a table in a private clinic room. The same researcher, who had prior experience of 
delivering the tool to healthy younger and older adults, 3,4,6,7 was present to lead the sessions 
and answer any questions upon request.  
Kinematic Motor Tests  
The KAT computerised tasks were presented on a tablet PC (screen = 260 x 163mm). For the 
Motor Tests, the screen was folded down horizontally to mimic a writing position (see Figure 
1), and patients used a digitising stylus in their preferred hand.  A battery of four tasks ran 
back-to-back with integrated onscreen instructions, each taking 3-5min to complete. 1,2,5-7  
(i) Tracking: participants kept the stylus on a dot as it moved around the screen in a figure-
of-eight (Figure 2a). Dot speed increased from Slow (4sec per figure-of-eight), to Medium 
(8sec) to Fast (16sec), with three repetitions at each speed (i.e. nine trials total).  The task 
was performed once with (µGuided¶) and once withoXWµ8QJXLGHG¶DVSDWLDOJXLGH(i.e. a 
figure-of-eight shape; Figure 2b). Root Mean Square Error (RMSE) was calculated as the 
average distance (mm) of the stylus from the closest reference point on the centre of the 
figure-of-eight. Higher RMSE values = reduced accuracy.  
(ii) Aiming: participants made discrete movements between dots that appeared in a recurring 
shape of a pentagram. The five movements comprising the pentagram shape repeated 
ten times (i.e. 50 movements; Figure 2c). Mean Movement Time (MT; time taken to 
complete all movements) was calculated, where lower MTs = reduced speed.  
(iii) Steering: participants traced a path, keeping the stylus within a moving box that 
progressed every 5sec (Figure 2d). Across six trials, the path shape became a mirror-
image of itself on every other trial. The moving box constrained speed, allowing accuracy 
to be compared across participants (since this limited speed-accuracy trade-offs). Shape 
Error (SE) was calculated by taking each traced path and analysing the difference in 
FRPSDULVRQWRDQµLGHDO¶UHIHUHQFHWKDWIHOOLQWKHH[DFWFHQWUHRISDWK+LJKHU6( UHGXFHG
accuracy.  
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Figure 1. An example of a participant (NB. not a patient from the present study) using the 
stylus to complete the KAT Tracking Task (Guided) on the tablet PC with the screen in the 
horizontal position. 
 
 
Figure 2. KAT tasks comprising the Kinematic Motor Test battery, completed by participants 
with a handheld stylus pen (Nb. Not to scale). (A) Tracking (Unguided). (B) Tracking (Guided). 
(C) Aiming. (D) Steering. 
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Sequence Learning Task  
A Sequence Learning Task was delivered on the same tablet PC with the screen in the 
standard vertical position, to allow patients a better view of the stimuli. Participants used a PC 
PRXVHDQGOHDUQHGDVHTXHQFHRIPRYHPHQWVPDGHWRHLJKWWDUJHWVRQWKHVFUHHQµ7UDLQLQJ¶
DQGµ7HVW¶WULDOVDOWHUQDWHGSURYLGLQJWHQRSSRUWXQLWLHVIRUSDrticipants to practice and recall a 
sequence (Training x10 + Test x10 = 20 trials). In the Training trials (Figure 3a), a central box 
was encircled by eLJKW LGHQWLFDO µWDUJHW¶ ER[HV )igures 3a-3b). An arrow appeared in the 
central box to indicate where to move the mouse (e.g. top left in Figure 3a) before returning to 
the centre. There were 16 moves that followed the same irregular pattern for every Training 
trial and, in between Training trials, patients recalled the sequence by moving the cursor back-
and-forth between the centre and targets as quickly and as accurately as possible without any 
arrow cues (Figures 3b- 3d). Two practices were given of a Training and Test trial (featuring 
a different 16-move sequence) before starting the experimental session. The full task took 
around 20-30min to complete, and a new 16-move sequence was used at the 6/52 session to 
avoid learning effects. 
 
Figure 3. KAT Sequence Learning Task, completed by participants with a standard PC mouse 
(Nb. Not to scale). (A) Training trial, requiring participants to move the dot into the box 
corresponding to the direction indicated by an arrow that appeared in the central box (e.g. top 
left in this example). (B) Example trajectories produced during a Training trial (C) Test trial 
whereby participants recalled the pattern of movements previously learned in the Training trial; 
and (D) Example trajectories produced during a test trial. 
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Standardised Clinical Outcome Measures 
Two measures of cognitive and psychomotor ability were administered, along with a disability 
scale, and two questionnaires to act as self-report measures of functional ability and 
psychological symptoms. The following tests were selected as they commonly appear in 
relevant literature. 1 
(i) Digit Symbol Substitution Test (DSST): A cognitive and psychomotor test involving 
matching symbols to their corresponding numbers in 90sec (max score = 93). 31 
This test was included as it has been used previously to determine changes in 
cognition following sedation and general anaesthesia. 32,33 Note that the DSST 
does not emphasise motor accuracy, because if symbols are copied in a legible 
manner, a point is always awarded ± participants can hence score higher by not 
paying attention to detail.  
(ii) $GGHQEURRNH¶V &RJQLWLYH ([DPLQDWLRQ-Revised (ACE-R) and Mini Mental State 
Evaluation (MMSE): Screening tools for Mild Cognitive Impairment and dementia. 
Sub-tests include Attention and Orientation, Memory, Fluency, Language and 
Visuospatial Ability (max score = 100).34 MMSE sub-items (max score = 30), and 
total ACE-R scores were calculated. ACE-R scores <88 give an 89% specificity for 
dementia, scores <82 give 100% specificity for dementia. The National Institute of 
Clinical Excellence (NICE) recommends a cut-off score of 27 for classifying 
absence of cognitive impairment. Our choice of the ACE-R and MMSE as cognitive 
measures is supported by their frequent use in populations where cognitive 
disturbance is expected. While these tests are designed ideally as a dementia 
screening tool, they have been used before to assess cognitive performance after 
stroke, albeit with some reported ceiling effects and questionable specificity. 34-39  
(iii) Glasgow Outcome Scale (GOS): Five-point global outcome scale, used to assess 
disability following brain injury and stroke. 40 Categories include Dead [1], 
Vegetative State [2], Severe Disability [3], Moderate Disability [4], Good Recovery 
[5].   
(iv) Self-Report Barthel Index (SRBI):  A questionnaire (max score = 20) for 
establishing independence in daily tasks. 41-43 The SRBI has often been cited in 
prior studies as a tool for documenting functional ability in stroke groups, though it 
notably has a ceiling effect and cannot detect minor motor impairments. 44-46 
(v) Hospital Anxiety and Depression Scale (HADs):  A self-report scale to detect 
symptoms of anxiety and depression. 47,48 Separate scores for Depression and 
Anxiety can be normal (1-7), borderline abnormal (8-10), or abnormal (11-21). The 
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decision to also record psychological symptoms stemmed from our experience of 
patients in outpatient clinics often reporting feelings of anxiety in relation to their 
diagnosis and/or recovery.  
Data Analysis 
For the Kinematic Motor Tests, mean RMSE, MT and SE across all trials were calculated for 
each participant and separate repeated-measures ANOVAs applied to compare performance 
between Discharge and 6/52 (NB. IBM SPSS Statistics for Windows, Version 21.0, was used 
for statistical analyses). One additional ANOVA was calculated for the Tracking tasks to 
analyse the effect of speed on RMSE. To determine whether motor performance was within a 
normal range, data were compared with scores in the healthy control group.  For this, the 
PHDQDQG&RQILGHQFH ,QWHUYDO &,RI WKHFRQWUROJURXS¶VSHUIRUPDQFHZDVXVHGDV WKH
FULWHULRQ IRU LGHQWLI\LQJ µQRUPDO¶ SHUIRUPDQFH E\ WKH SDWLHQWV =-scores on each task were 
calculated (using the mean and SD of healthy controls) and an average taken for each patient. 
A z-score of -.35 or less indicates performance outside of mean + 95% CI.  
In the Sequence Learning Test, the accuracy of recall during the Test trials was indicated by 
the maximum number of moves performed in the correct sequential order (Correctly Recalled; 
CR; max score = 16; points not deducted for incorrect moves) across all trials, and these 
scores were compared between Discharge and 6/52 follow-up.  Performance was compared 
to a control group of healthy adults (N = 32) with the same average age as the patients (mean 
= 52.36, SD = 25.1).  Average group performance minus 95% CI (CR = 9 - 2) was the cut-off 
FULWHULDIRULGHQWLI\LQJµQRUPDO¶SHUIRUPDQFH the patients. 
Statistical analysis was not completed on the standardised clinical outcome measures, rather, 
scores at each testing session were merely calculated and recorded to compare for changes 
across time. The inclusion of these tests was to test the hypothesis that standardised tests fail 
to detect changes that can otherwise be registered by more objective sensitive measures, like 
the kinematic tests used in the present research.  
Results  
Standardised Clinical Outcome Measures 
Most standard measures did not differ markedly between sessions. Because of the 
categorical/ordinal nature of these scores, the limited change in scores and the small numbers 
of participants; it is not useful to examine these data using grouped statistical methods. 
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Instead, we examined measures for each individual and compared individual scores with 
ceiling performance on the tests. There was no change in GOS between sessions, as nine 
patients received the highest classification LHµ*RRG5HFRYHU\¶) at Discharge and 6/52. One 
patient was scored as KDYLQJ µModerate DLVDELOLW\¶ VFRUH DWDischarge and 6/52. The 
pattern was similar for SRBI ± six patients ZHUHµIXQFWLRQDOO\LQGHSHQGHQW¶ (score = 20) at both 
sessions, one patient scored 19 at both sessions, and one patient scored 18 at Discharge and 
17 at 6/52. There were also no systematic changes in the HADs measure. At Discharge, four 
of eight patients KDGµborderline abnormal¶ or µabnormaO¶ Anxiety scores (scores = 8, 8, 8, 12), 
and at 6/52, 2 scores remained unchanged as µborderline abnormal¶, with one patient going 
from µnormal¶ to µabnormal¶(6 to 16) and another from µabnormal¶ to¶ normal¶ (12 to 6). On the 
Depression scale, two scores were µabnormal¶ or µborderline abnormal¶ at Discharge and at 
6/52. Raw data for the SRBI and the HADs subscales is given in Table 1.  
 
The only standardised measures that showed systematic changes were the ACE-R and 
DSST. The ACE-R scores for six of eight patients improved from Discharge to 6/52 (mean = 
93 increasing to 98) to scores that are near to maximum. This increase seemed to be driven 
mainly by improved Memory scores on the ACE-R (measuring recall, anterograde memory 
and retrograde memory), with an average increase from 21 to 25 out of 26 for the Memory 
component. The remaining two individuals who did not improve on the Memory element 
(scores at Discharge = 12 and 14; 6/52 = 21 and 19 respectively) also performed poorly (i.e. 
scores <88, which is the cut-off with 94% sensitivity and 89% specificity for dementia) across 
the whole ACE-R at both testing sessions. Interestingly, neither of these patients fell below 
the MMSE cut-off for cognitive impairment (both patients scored 27 on the MMSE, which if 
one point less, would have indicated cognitive impairment). In fact, there were no reliable 
changes in the MMSE subtest of the ACE-R across the whole group, with most participants 
scoring the same at both sessions. The other remaining ACE-R sub-tests also failed to 
display any impairment (e.g. all except one patient scored 15-16 for Visuospatial Ability at 
both sessions).  Finally, DSST scores improved for six of ten patients, as scores improved 
from 45 points at Discharge to 60 points (out of 93) by 6/52. Scores for the other four 
individuals either remained the same at both sessions (i.e. DSST score = 45 at both 
sessions for three patients) or declined between sessions (DSST reduced from 35 to 25 for 
one patient).  
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Table 1. Individual patient scores on standardised outcome measures and kinematic tests at Discharge (Dis.) and 6/52 weeks post-operation 
(6/52). The age of each participant is given, along with the following individual patient scores on (i) SRBI (max = 20); (ii) Anxiety (A) and Depression 
(D) subscales of HADs (max = 21 per subscale); (iii) Maximum number of items Correctly Recalled (CR) out of the full 16 movement sequence 
comprising the Sequence Learning Task; (iv) a composite measure of Motor Performance (z-scores) on the Motor Task battery, including 
Tracking, Steering and Aiming tests (i.e. a Motor measure); (v) ACE-R (max = 100); and (vi) DSST (max = 93). Impaired performance measures 
are highlighted in red text. Dark grey shaded cells highlight patients with impaired CR at 6/52, and Light grey shaded cells highlight those with 
Motor difficulties at 6/52. For clarity values of ACE-R and DSST that are inconsistent with CR and Motor impairments have been emboldened 
and marked with a box.  
   
             
  
SRBI 
 
HADS(A) 
 
HADS(D) 
 
CR 
 
Motor 
 
ACE-R 
 
DSST 
 
P Age Dis. _6/52 Dis. _6/52 Dis. _6/52 Dis. 6/52 Dis. 6/52 Dis. 6/52 Dis. 6/52 
#1 52 20 20 6 2 2 2 7 5 -1.35 -0.16 84 85 51 51 
#2 74 20 20 8 8 4 2 4 6 -2.49 -0.91 #N/A #N/A 27 27 
#3 54 20 20 12 6 8 0 7 6 -0.87 -0.35 92 98 38 48 
#4 72 20 20 0 0 0 0 2 6 -3.38 0.14 82 82 17 30 
#5 68 20 20 8 8 3 1 5 6 -1.12 0.59 94 99 56 62 
#6 31 20 20 3 2 1 1 2 9 0.99 1.34 92 95 43 75 
#7 55 19 19 6 16 5 8 10 13 -1 -0.38 100 99 64 79 
#8 49 18 17 8 7 10 9 10 16 -2.32 0.23 89 97 35 25 
#9 49 #N/A #N/A #N/A #N/A #N/A #N/A 16 16 0.79 1.12 #N/A #N/A 55 55 
#10 24 #N/A #N/A #N/A #N/A #N/A #N/A 16 16 0.75 1.44 93 99 52 65 
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Kinematic Motor Tests 
Analyses of the Tracking task showed patients improved performance accuracy from 
Discharge to 6/52 () SȘS mean RMSE at Discharge = 17.10 
mm; 6/52 = 12.27 mm). Accuracy also increased as dot-tracking speed reduced (LH µ6ORZ¶
Tracking; F ( SȘS  İ  ). There were no session x speed 
interactions suggesting performance improved between sessions similarly for all speeds. A 
single measure across speeds was taken to simplify further analysis. This µFRPELQHG¶measure 
showed seven out of ten patients exhibited µabnormal¶ Tracking performance at Discharge (i.e. 
worse than mean healthy FRQWUROV¶ performance + 95% CI; t(18) = 1.93, p < .05). Furthermore, 
despite all patients showing some degree of improvement, two patients still exhibited 
µDEQRUPDO¶7racking at 6/52 (Figure 4).  
A similar pattern was seen in the other Motor Tests (Figure 5). The steering task detected 
impaired accuracy compared to controls at discharge (t(18) = 2.02, p < .05) and accuracy 
improved from Discharge to 6/52 ) SȘS  ± all patients improved 
to some degree; but three of ten were still abnormal at 6/52. Aiming performance was only 
marginally worse compared to controls at discharge (t(18) = 1.58, p = .074) but this group 
performance still improved between Discharge (mean MT = 1.67sec) and 6/52 mean MT = 
1.37sec) with shorter duration movements for seven of ten patients (t(9) = 2.12, p<.05), though 
movement duration was still µabnormal¶ for two patients at 6/52.  These findings suggest that 
our KAT Motor Tests were sufficiently sensitive to detect improvements in performance 
between sessions, and identify individuals that had not yet fully recovered (through comparing 
performance with healthy controls). 
Sequence Learning Task  
Analyses of the maximum number of moves that patients could recall across the Sequence 
Learning Task (i.e. CR) showed that only two patients correctly recalled all 16 moves in both 
sessions (i.e. showing no impairment and thus no room for improvement). Four patients 
improved by 2-6 correct responses from Discharge to 6/52 (some data were not recorded for 
two patients at Discharge due to disruptions on the ward, hence initial performance could not 
be assessed), but at 6/52 there were still five patients who could only recall 5-6 items correctly 
(out of 16). Two of these patients also struggled with the ACE-R Memory sub-tests (Patients 
1 and 4 in Table 1), but the other three scored normally on the ACE-R (i.e. no clear cognitive 
impairment identified by the ACE-R). 
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Figure 4. Mean Root Mean Square Error (RMSE; mm) in the Tracking Tasks of the Motor 
Control Battery (KAT; Nb. data from Unguided and Guided versions has been combined) in 
the Slow, Medium and Fast Speed Tracking conditions, recorded at Discharge (white bars) 
DQGDW GDUNJUH\EDUV IRUSDWLHQWV µ3WV¶DVFRPSDUHGZLWKDKHDOWK\FRQWUROJURXS
EODFNEDUVµ&RQWUROV¶/DUJHU506(YDOXHVLQGLFDWHUHGXFHG accuracy. The bars represent 
the standard error of the mean (SEM) 
  
Figure 5. Aiming and Steering Tasks from the Motor Control Battery (KAT), recorded at 
'LVFKDUJHZKLWHEDUVDQGDWGDUNJUH\EDUVIRUSDWLHQWVµ3WV¶DVFRPSDUHGZLWKD
healthy FRQWURO JURXS EODFN EDUV µ&RQWUROV¶ /DUJHU YDOXHV LQGLFDWH ZRUVH SHUIRUPDQFH
(slower time or greater shape error). The bars represent the standard error of the mean (SEM) 
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Discussion  
In the present pilot study, we examined the efficacy of KAT (a system previously shown to 
detect discrepancies in performance in young and older healthy groups 1-8) for detecting post-
operative changes in movement and cognition in patients with UA and aSAH. Aneurysmal 
Subarachnoid Hemorrhage (aSAH) is associated with motor and cognitive deficits, which can 
lead to reduced quality of life. 10,11,16,17 Less is known about the outcomes of preventative IAT 
for UA, though anecdotal reports suggest elective IAT is not entirely free of side effects either.  
There is no doubt that IAT improves a patient's chance of survival, but current methods for 
assessing long-term outcomes lack the sensitivity necessary for identifying subtle neurological 
problems. The physician might consider the patient as havinJPDGHDµ*RRG5HFRYHU\¶(e.g. 
based on global disability scales, such as GOS 18) yet patients often complain of anxiety (e.g. 
fear of stroke), memory problems, and an inability to resume the same level of employment 
prior to IAT. 16,17 The lack of sensitive measures makes it difficult to properly evaluate the 
relative costs and benefits of intervention. The potential costs of treatment may be drastically 
underestimated if the measures lack the sensitivity to identify subtle yet important 
impairments. This issue may be of less consequence when the choice is between IAT and 
severe disability (i.e. following an aSAH); however, it could be critical when deciding upon a 
treatment regime for an individual with UA (particularly a small aneurysm), when IAT is a 
choice, not an emergency. 
To determine whether more sensitive tests could be composed, we administered standardised 
clinical outcome measures and novel kinematic tests at Discharge and 6/52 post-IAT. Two 
tests of functional ability (GOS and SRBI) were used as a marker of how independent patients 
were in daily activities after IAT. The GOS provides a global measure of disability, and while 
quick and easy to administer, there are concerns in the literature over its lack of specificity 
between categories, mostly when distinguishing between 'Moderate' and 'Severe' disability. 
40
. In our study, GOS scores did not change between Discharge and 6/52, and nine of ten 
patients were classed as having made a 'Good Recovery' with only a single patient rated as 
µ0RGHUDWHO\ 'LVDEOHG¶ at both time-points. The SRBI is a more comprehensive test of 
functional outcome, but this also showed no difference in scores between Discharge and 6/52; 
with seven of eight SDWLHQWVFODVVLILHGDVµIXOO\LQGHSHQGHQW¶LQDFWLYLWLHVRIGDLO\OLYLQJ at both 
sessions (see Table 1).  
There were only two clinical measures that appeared to detect improvements in the patients 
between sessions, which were the ACE-R and DSST. Whilst most ACE-R subcomponents 
remained stable, the Memory sub-test improved in six of eight patients, with performance 
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essentially reaching ceiling for these individuals at 6/52, to suggest a full recovery (see Table 
I).  With the DSST there were only improvements in six of ten patients. Even though the DSST 
has been shown to correlate strongly with age (due to age-related declines in psychomotor 
ability 49) it is unclear whether this test was sufficiently sensitive to detect the subtle changes 
experienced by the patient population studied here. This finding is discussed later when 
comparing the DSST to the kinematic motor measures. 
One issue that did materialise via standardised testing, was the frequency of patients 
experiencing psychological symptoms, which was indexed by the HADs. During the testing 
period, patients regularly expressed significant concern about being diagnosed with UA, and 
felt unrest when trying to make their decision about treatment (e.g. surgical versus 
endovascular methods). Anxiety often plays a role in decisions to treat.50 Some patients can 
harbour feelings of worry and anxiety when an UA is left untreated, 50 yet 50% of patients in 
RXUVWXG\VFRUHGDVµborderline abnormal¶RQWKH+$'V$nxiety scale at Discharge, even 
though their aneurysms had been successfully treated. Verbal reports during testing did 
indeed reveal that the most common concerns were recurrence of an UA, or another aSAH 
happening in the future.  
In contrast with the µpen-and-paper¶ standardised tests, our novel Kinematic Motor and 
Sequence Learning Tests reliably detected changes in performance at the Discharge testing 
session post-IAT, as well as functional recovery across the patient group at 6/52. The Motor 
Tests could identify four individuals that were experiencing movement difficulties at 6/52 (see 
light grey shaded cells in Table I; patients 1-3, 7). The Sequence Learning Test also identified 
six patients (see dark grey shaded cells in Table I; SDWLHQW¶V 1-6) exhibiting cognitive difficulties 
at 6/52. Whilst there was some overlap between the Motor and Sequence Learning Tests 
scores (i.e. patients 1-3 struggled on both tasks), the ACE-R failed to detect performance 
difficulties for patient 3, and the DSST did not detect marked performance difficulties relative 
to healthy age-matched individuals for patients 1 and 3 (see bold text in rightmost columns of 
Table 1). There was one patient that exhibited motor problems without memory problems 
(patient 7) which was not identified by the DSST, and another two patients that exhibited 
memory problems without motor problems (patients 5-6) which equally was not identified by 
the ACE-R. There was a single patient (patient 8) identified with problems via the DSST that 
was not highlighted as being outside of the normal range using the composite Tracking Motor 
Test measure, but the Aiming sub-test did identify performance outside the normal range for 
this individual. This result suggests that future research may show that specific types of task 
provide greater specificity (i.e. that tracing relies upon feed-forward control mechanisms that 
can be affected in isolation after IAT treatment).  
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The present findings have multiple implications, not only for improving the methods used to 
assess SDWLHQWV¶ post-,$7EXWDOVRIRULQIRUPLQJSDWLHQWV¶GHFLVLRQWRXQGHUJR,$7HOHFWLYHO\
In elective cases, the surgeon and patient must weigh up the evidence to decide whether to 
treat the UA (usually based on location and size) and, if so, which method to use (i.e. 
endovascular or neurosurgical). It is vital that the relatively insensitive measures used at 
present are improved, since more informative measures could determine whether IAT for UA 
can cause disturbances in motor and cognitive function (even in the absence of a 
haemorrhage). This evidence would provide further information for the surgeon and patient to 
consider when calculating the potential risks of undergoing IAT as a preventative measure. 51  
Furthermore, in the future we aim to use KAT in larger and more diverse clinical groups, to 
establish markers of recovery that would be a useful adjunct to the current standardised 
outcomes measures used when assessing rehabilitative efforts. The present work is the first 
step towards achieving this, as is highlights the feasibility of administrating KAT in clinical 
contexts (i.e. at bedside and in clinic settings), and its capacity to detect minor changes in 
movement and cognition.   
In summary, KAT provides a useful method for measuring the outcomes associated with IAT, 
and thus has the potential for use as an assessment tool in other similar clinical populations. 
Future studies employing kinematic analysis will allow: (i) improved understanding of the 
nature and longevity of subtle deficits associated with IAT; and (ii) exploration of the 
differences in outcomes of IAT between treatment methods (i.e. endovascular vs. 
neurosurgical). More generally, KAT tasks can be developed to examine the neural 
underpinnings of post-operative deficits, by comparing kinematic data with structural changes 
in the brain. It may also help gather information to inform screening methods that support post-
operative care, and subsequent rehabilitation programmes.  
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